Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Blood (2012) 120 (21): 3949.

https://doi.org/10.1182/blood.V120.21.3949.3949

Published: 2012

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial

María-Victoria Mateos, MD, PhD, Albert Oriol, Ana-Isabel Teruel, Enrique Bengoechea, Montse Pérez, Javier López, Joaquín Díaz-Mediavilla, Jose Mariano Hernández, Felipe de Arriba, Yolanda Gonzalez, Joan Bladé, MD, Juan José Lahuerta, JesÃ°s F. San Miguel

Blood (2011) 118 (21): 477.

https://doi.org/10.1182/blood.V118.21.477.477

Published: 2011

Journal Articles

Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Blood (2011) 118 (21): 991.

https://doi.org/10.1182/blood.V118.21.991.991

Published: 2011

Journal Articles

Multiparameter Flow Cytometry Analysis of Peripheral Blood T, NK and Dendritic Cells From High-Risk Smoldering Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone

Bruno Paiva, Lucía López-Corral, María-Belén Vidriales, Luis Ignacio Sánchez Abarca, Miguel T. Hernandez, Joan Bargay, Javier De La Rubia, Pilar Giraldo, Ana-Isabel Teruel, Laura Rosiñol, Albert Oriol, Jose Hernández, Felipe de Arriba, Graça Esteves, Jose Antonio Pérez Simón, María-Victoria Mateos, Jesus F San Miguel

Blood (2010) 116 (21): 1906.

https://doi.org/10.1182/blood.V116.21.1906.1906

Published: 2010

Journal Articles

Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Blood (2010) 116 (21): 1935.

https://doi.org/10.1182/blood.V116.21.1935.1935

Published: 2010

Journal Articles

Competition Between (Mono)Clonal Plasma Cells and Normal Cells for Potentially Overlapping Bone Marrow Niches Is Associated with a Progressively Altered Cellular Distribution In MGUS Vs. Myeloma

Blood (2010) 116 (21): 617.

https://doi.org/10.1182/blood.V116.21.617.617

Published: 2010

Journal Articles

Utility of Multiparameter Flow Cytometry Immunophenotypic Studies In Patients with Systemic Light Chain (AL) Amyloidosis

Bruno Paiva, María-Belén Vidriales, Jose J. Perez, Maria-Consuelo López-Berges, Ramón García-Sanz, Enrique M. Ocio, Rebeca Garcia, Alfonso Garcia de Coca, Emilia Pardal, Magdalena Sierra, Jose Hernández, Natalia de las Heras, Josefina Galende, Jose Maria Alonso, Abelardo Bárez, María-Victoria Mateos, Jesus F San Miguel

Blood (2010) 116 (21): 4051.

https://doi.org/10.1182/blood.V116.21.4051.4051

Published: 2010

Journal Articles

Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials

Blood (2010) 116 (21): 1910.

https://doi.org/10.1182/blood.V116.21.1910.1910

Published: 2010

Journal Articles

Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience

Adrian Alegre, Albert Oriol-Rocafiguera, Jose García-Laraña, María-Victoria Mateos, Anna Sureda, MD, PhD, Carmen Martínez Chamorro, María Teresa Cibeira, MD, PhD, Robert Knight, MD, Barbara Rosettani

Blood (2010) 116 (21): 3045.

https://doi.org/10.1182/blood.V116.21.3045.3045

Published: 2010

Journal Articles

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Blood (2010) 116 (21): 309.

https://doi.org/10.1182/blood.V116.21.309.309

Published: 2010

Journal Articles

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

María-Victoria Mateos, MD, PhD, Juán-José Lahuerta, MD, PhD, Anna Sureda, MD, PhD, Javier de la Rubia, MD, PhD, Ramón García-Sanz, MD, PhD, Rafael Martínez, MD, PhD, José García-Laraña, MD, PhD, Felipe de Arriba, MD, PhD, Jose-María Ribera, MD, PhD, Miguel-Teodoro Hernández, MD, PhD, Lourdes Escoda, MD, PhD, Dolores Carrera, MD, PhD, Joan Besalduch, MD, PhD, B. Hernández, MD, PhD, P. Fernández, MD, PhD, Joan Blade, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 937.

https://doi.org/10.1182/blood.V110.11.937.937

Published: 2007

Journal Articles

Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.

María-Dolores Caballero, MD, PhD, Rodrigo Martino, MD, María-Victoria Mateos, MD, Phd, Javier Briones, MD, Javier de la Serna, MD, Jose-Francisco Tomás, MD, Reyes Arranz, MD, Jose-Luis Díez, MD, Vicente Rubio, MD, Josep-María Ribera, MD, José-María Moraleda, MD, PhD, Guillermo Sanz, MD, Alvaro Urbano, MD, PhD, José Sarrá, MD, Antonia Sampol, MD, Jordi Sierra, MD, PhD, J. F. San Miguel, MD, PhD

Blood (2006) 108 (11): 3024.

https://doi.org/10.1182/blood.V108.11.3024.3024

Published: 2006

Journal Articles

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

Blood (2006) 108 (7): 2165–2172.

https://doi.org/10.1182/blood-2006-04-019778

Published: 2006

NARROW

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Maintenance Therapy with Bortezomib Plus Thalidomide (VT) or Bortezomib Plus Prednisone (VP) In Elderly Myeloma Patients Included In the GEM2005MAS65 Spanish Randomized Trial

Smoldering Multiple Myeloma (SMM) At High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) As Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Multiparameter Flow Cytometry Analysis of Peripheral Blood T, NK and Dendritic Cells From High-Risk Smoldering Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone

Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

Competition Between (Mono)Clonal Plasma Cells and Normal Cells for Potentially Overlapping Bone Marrow Niches Is Associated with a Progressively Altered Cellular Distribution In MGUS Vs. Myeloma

Utility of Multiparameter Flow Cytometry Immunophenotypic Studies In Patients with Systemic Light Chain (AL) Amyloidosis

Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials

Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience

Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination

Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).

Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only